First Time Loading...

Dyadic International Inc
NASDAQ:DYAI

Watchlist Manager
Dyadic International Inc Logo
Dyadic International Inc
NASDAQ:DYAI
Watchlist
Price: 1.67 USD 2.45% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

DYAI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. [ Read More ]

The intrinsic value of one DYAI stock under the Base Case scenario is 2.25 USD. Compared to the current market price of 1.67 USD, Dyadic International Inc is Undervalued by 26%.

Key Points:
DYAI Intrinsic Value
Base Case
2.25 USD
Undervaluation 26%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Dyadic International Inc

Backtest DYAI Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DYAI stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Dyadic's Productivity Surge and Revenue Prospects
2023-Q3 Earnings Call

Dyadic's Productivity Surge and Revenue Prospects

Dyadic accelerated momentum in 2023 with its innovative C1 technology and Dapibus platform, making strides in protein and enzyme production for pharmaceutical and non-pharmaceutical markets. They reported advancements such as animal-free recombinant serum albumin close to commercialization and productivity unmatched by traditional platforms - C1 is up to 300x more productive than some methods. Despite global economic headwinds affecting R&D funding, Dyadic secured new partnerships, upfront payments, and fully funded projects, with prospects of near-term revenue from high-value products that bypass lengthy trials. The potential for consistent revenue comes from an internal product pipeline and external collaborations expected to mature in the coming year.

Financials

Balance Sheet Decomposition
Dyadic International Inc

Current Assets 9.1m
Cash & Short-Term Investments 8.2m
Receivables 430k
Other Current Assets 490k
Non-Current Assets 170k
PP&E 150k
Other Non-Current Assets 20k
Current Liabilities 1.5m
Accrued Liabilities 670k
Other Current Liabilities 790k
Non-Current Liabilities 140k
Other Non-Current Liabilities 140k
Efficiency

Earnings Waterfall
Dyadic International Inc

Revenue
3m USD
Cost of Revenue
-2.3m USD
Gross Profit
620k USD
Operating Expenses
-8.9m USD
Operating Income
-8.2m USD
Other Expenses
1.4m USD
Net Income
-6.9m USD

Free Cash Flow Analysis
Dyadic International Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DYAI Profitability Score
Profitability Due Diligence

Dyadic International Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive 1-Year Revenue Growth
21/100
Profitability
Score

Dyadic International Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

DYAI Solvency Score
Solvency Due Diligence

Dyadic International Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Dyadic International Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DYAI Price Targets Summary
Dyadic International Inc

Wall Street analysts forecast DYAI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DYAI is 7.65 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

Lowest
Price Target
6.06 USD
263% Upside
Average
Price Target
7.65 USD
358% Upside
Highest
Price Target
9.45 USD
466% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DYAI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DYAI Price
Dyadic International Inc

1M 1M
+24%
6M 6M
-13%
1Y 1Y
+12%
3Y 3Y
-68%
5Y 5Y
-49%
10Y 10Y
+12%
Annual Price Range
1.67
52w Low
1.29
52w High
2.38
Price Metrics
Average Annual Return -4.51%
Standard Deviation of Annual Returns 54.52%
Max Drawdown -88%
Shares Statistics
Market Capitalization 48.1m USD
Shares Outstanding 28 811 100
Percentage of Shares Shorted 0.85%

DYAI Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Dyadic International Inc Logo
Dyadic International Inc

Country

United States of America

Industry

Biotechnology

Market Cap

48.1m USD

Dividend Yield

0%

Description

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The firm is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.

Contact

FLORIDA
Jupiter
140 Intracoastal Pointe Dr Ste 404
+15617438333.0
http://www.dyadic.com/

IPO

2004-11-05

Employees

7

Officers

Founder, CEO, President & Director
Mr. Mark A. Emalfarb
Chief Financial Officer
Ms. Ping Wang Rawson CPA, M.B.A.
Chief Business Officer
Mr. Joseph P. Hazelton
Executive Vice President of Business Development
Mr. Doug Pace B.A.
Secretary of the Board
Ms. Ana Gómez Rodriguez

See Also

Discover More
What is the Intrinsic Value of one DYAI stock?

The intrinsic value of one DYAI stock under the Base Case scenario is 2.25 USD.

Is DYAI stock undervalued or overvalued?

Compared to the current market price of 1.67 USD, Dyadic International Inc is Undervalued by 26%.